# PSMB8

Source: https://onco.cc/targets/psmb8/  
OnCo record `psmb8` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PSMB8 (Proteasome subunit beta type-8) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Gastric & gastro-oesophageal junction cancer, Non-Hodgkin lymphoma and 1 more.

## Summary

The proteasome is a multicatalytic proteinase complex which is characterised by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.95, genetic association 0.00, clinical 0.99).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: proteasome 20S subunit beta 8; Proteasome subunit beta type-8; RING10; D6S216E; PSMB5i; beta5i; LMP7
- Tags: cancer-genes-wave
- Symbol: PSMB8
- Class: enzyme
- Biology: The proteasome is a multicatalytic proteinase complex which is characterised by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Involved in the generation of spliced peptides resulting from the ligation of two separate proteasomal cleavage products that are not contiguous in the parental protein. Acts as a major component of interferon gamma-induced sensitivity. Location: Cytoplasm; Nucleus (UniProt). Locus 6p21.32 (HGNC).
- Where found: Multiple myeloma: Open Targets association 0.62 with plasma cell myeloma (MONDO_0009693); Gastric & gastro-oesophageal junction cancer: CIViC evidence names this disease; Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908); Mantle cell lymphoma: Open Targets association 0.54 with mantle cell lymphoma (MONDO_0018876)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99; CIViC holds 1 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9545: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9545
- UniProt P28062: https://www.uniprot.org/uniprotkb/P28062/entry
- NCBI Gene 5696: https://www.ncbi.nlm.nih.gov/gene/5696
- Ensembl ENSG00000204264: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204264

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/psmb8.json